Coronavirus (COVID-19)
Learn more
May 09, 2017
Sponsor: Bristol-Myers Squibb
Number: CA209370
The purpose of this study is to determine whether Nivolumab monotherapy or in combination with Standard of care (SOC) therapies will provide clinical benefit (i.e., PFS, OS, and DOR) without unacceptable toxicity in advanced Non-Small Cell Lung Cancer patients.
Who’s eligible:
Available at: Backus Hospital- Eastern Connecticut Hematology and Oncology.
Referral Line: 860.972.4700
Get the latest healthcare news directly in your inbox.
Sign up for text alerts / Text MoreLife to 31996.